BioSpace News Archive

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 third quarter on Monday, November 9, 2020 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments. What: Stereotaxis

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activator VSJ-110 (previously known as CFTR act -K267) for the treatment of allergic co

Experienced Six Sigma healthcare executive bolsters leadership team at key juncture; will work closely with Dr. Patrick Soon-Shiong who will serve as Executive Chairman

Imagin Medical (CSE:IME) (OTCQB:IMEXF) (Frankfurt & Stuttgart Symbol:DPD2) (“Imagin” or the “Company”) today announced the agenda for its virtual investor event taking place on Thursday, October 29, 2020 at 12:00 pm Eastern Daylight Time.

ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the appointment of Dr. Stewart Craig as its Chief TechnicalOfficer (CTO) and member of the executive team.

Drawbridge Health, a healthcare technology company redefining the blood draw experience for both patients and healthcare providers, announced a further investment from Sumitomo Dainippon Pharma Co., Ltd. as well as a new research and development collaboration agreement.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States.

Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its 2020 third quarter operating results on Tuesday, November 10, 2020, after market close.

EpicGenetics announced a contract with the Mayo Clinic Fibromyalgia and Chronic Fatigue Clinic to perform research to investigate the use of the EpicGenetics FM/a® Test to determine the test’s use and applicability to objectively diagnose fibromyalgia

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a virtual Emerging Technologies in Diagnostics Symposium from 10 a.m. to 1 p.m. ET on Thursday, Oct. 29.